Sumeet Bhanvadia, Sumanta K. Pal

Nature Reviews Urology Volume 15, pages 530–532 (2018)
DOI: 10.1038/s41585-018-0064-3

Cytoreductive nephrectomy, a standard approach for de novo metastatic renal cell carcinoma in the era of cytokine therapy, has been upheld during the age of targeted therapy on the basis of retrospective data. Now, the first level I prospective data from the CARMENA and SURTIME trials challenge this standard.